Splash_Beverage_Group Licenses CannEpil Globally
Analysis based on 14 articles · First reported Jul 06, 2026 · Last updated Jul 06, 2026
The market is likely to react positively to Splash Beverage Group's acquisition of CannEpil, as it signifies a strategic shift into the biopharmaceutical sector with a product that has existing international commercialization and U.S. regulatory progress. This could lead to increased investor confidence in Splash Beverage Group's growth potential and a potential rise in its stock price. For GT Biopharma, the debt forgiveness and royalty agreement provide financial stability and a share in future success, which may also be viewed favorably by its investors.
Splash Beverage Group has entered into an exclusive global licensing agreement with GT Biopharma for CannEpil, a cannabinoid-based therapeutic for drug-resistant epilepsy. This agreement grants Splash Beverage Group worldwide rights to develop, commercialize, and sell CannEpil for an initial twenty-year term. The transaction involves Mercer Street Global Opportunity Fund forgiving approximately $5 million of GT Biopharma's debt and Splash Beverage Group issuing $5.5 million in preferred equity to GT Biopharma. Additionally, C/M Capital Partners committed a $1 million strategic investment to Splash Beverage Group to support CannEpil's regulatory advancement and commercialization, particularly in the United States. CannEpil is already available in markets like Republic of Ireland, the United Kingdom, Germany, and Australia, and has initiated engagement with the United States — Food and Drug Administration for U.S. clinical development.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard